Drug Type Fusion protein |
Synonyms PD-1-dependent IL12 |
Target |
Mechanism IL-12 stimulants(Interleukin-12 stimulants), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Bonum Therapeutics, Inc.Startup |
Active Organization Bonum Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Bonum Therapeutics, Inc.Startup | 30 Apr 2024 |